In the late 1800s and early 1900s, anti-Chinese sentiment in the United States w...
CSL Behring, a prominent player in the Australian pharmaceutical landscape, rece...
In November, regulators overseeing pharmaceutical standards in the U.S. identifi...
Gilead Sciences has agreed to purchase CymaBay Therapeutics for $4.3 billion, ai...
Unlearn, a developer specializing in digital replicas, recently disclosed its at...
The US FDA has granted fast track designation to Edgewise Therapeutics’ EDG-5506...
BioAge Labs has secured $170m in an Series D funding round to progress the devel...
Ipsen reported that the US FDA approved the Onivyde regimen (NALIRIFOX) as a fir...
Two FDA representatives FDA spoke at the ongoing 2024 SCOPE Summit about how the...
A bipartisan group of lawmakers is seeking an investigation and sanctions agains...
A panel at the 2024 SCOPE Summit shared their experiences of setting up and runn...
The FDA has issued warning letters to two online sellers for selling unapproved ...
The partnership will focus on designing molecular glues for unspecified therapeu...
Grifols’ Phase III AdFIrst trial met its primary endpoint and the company plans ...
Sudo Biosciences secured $30m in second round of Series B funding to further the...
A Food and Drug Administration advisory panel lent its support to Abbott's new d...
